HaloMD achieved a major legal win today in the U.S. District Court for the Eastern District of Texas, where Judge Robert W. Schroeder III dismissed all seven claims filed by Blue Cross Blue Shield of Texas (BCBS Texas), a subsidiary of Chicago-based Health Care Service Corporation (HCSC), against HaloMD and its co-defendants. The dismissal was issued with prejudice, preventing the claims from being refiled.
In an 18-page opinion, the Court rejected BCBS Texas’s effort to challenge the protections and finality established under the No Surprises Act (NSA) and the Independent Dispute Resolution (IDR) system. The ruling criticized the insurer’s attempt to revisit matters already decided through arbitration, noting that “the collateral attack doctrine is even more clearly applicable where, as here, Plaintiff is attempting to relitigate issues previously decided by the IDR entities.” The Court applied the same reasoning to disputes connected to Texas Senate Bill 1264 and the state’s IDR framework.
“The Court’s decision correctly reinforces the law,” said Justin Carangelo, General Counsel and Chief Compliance Officer at HaloMD. “The No Surprises Act limits judicial review of IDR determinations. This marks the fourth federal court ruling in six weeks rejecting attempts to weaken the statute. Insurers pursuing similar litigation should reconsider whether such actions represent a productive use of resources.”
Patrick Velliky, HaloMD’s Chief External Affairs Officer, stated that the ruling still leaves unresolved concerns regarding unpaid obligations under the No Surprises Act. According to HaloMD, BCBS Texas and its parent company HCSC continue to owe healthcare providers tens of millions of dollars tied to overdue, legally binding IDR awards for patient care already delivered.
The dismissal adds to a growing series of court decisions upholding the IDR process. Comparable lawsuits involving HaloMD and unrelated defendants have recently been dismissed in several federal jurisdictions, including the Central District of California, the Middle District of Florida, and the Eastern District of Pennsylvania.
The No Surprises Act, which became effective on January 1, 2022, was enacted to shield patients from unexpected medical bills. The legislation established the IDR system as the official process for settling reimbursement disputes between insurers and out-of-network providers, while protecting patients from costs beyond standard in-network obligations. Texas Senate Bill 1264, passed in 2019, created a similar state-level dispute resolution process with strict limitations on court review. Under both systems, IDR decisions are intended to be final and binding.
The matter is captioned Blue Cross Blue Shield of Texas v. HaloMD, LLC et al., Case No. 5:25-CV-132-RWS (E.D. Tex.).
In an 18-page opinion, the Court rejected BCBS Texas’s effort to challenge the protections and finality established under the No Surprises Act (NSA) and the Independent Dispute Resolution (IDR) system. The ruling criticized the insurer’s attempt to revisit matters already decided through arbitration, noting that “the collateral attack doctrine is even more clearly applicable where, as here, Plaintiff is attempting to relitigate issues previously decided by the IDR entities.” The Court applied the same reasoning to disputes connected to Texas Senate Bill 1264 and the state’s IDR framework.
“The Court’s decision correctly reinforces the law,” said Justin Carangelo, General Counsel and Chief Compliance Officer at HaloMD. “The No Surprises Act limits judicial review of IDR determinations. This marks the fourth federal court ruling in six weeks rejecting attempts to weaken the statute. Insurers pursuing similar litigation should reconsider whether such actions represent a productive use of resources.”
Patrick Velliky, HaloMD’s Chief External Affairs Officer, stated that the ruling still leaves unresolved concerns regarding unpaid obligations under the No Surprises Act. According to HaloMD, BCBS Texas and its parent company HCSC continue to owe healthcare providers tens of millions of dollars tied to overdue, legally binding IDR awards for patient care already delivered.
The dismissal adds to a growing series of court decisions upholding the IDR process. Comparable lawsuits involving HaloMD and unrelated defendants have recently been dismissed in several federal jurisdictions, including the Central District of California, the Middle District of Florida, and the Eastern District of Pennsylvania.
The No Surprises Act, which became effective on January 1, 2022, was enacted to shield patients from unexpected medical bills. The legislation established the IDR system as the official process for settling reimbursement disputes between insurers and out-of-network providers, while protecting patients from costs beyond standard in-network obligations. Texas Senate Bill 1264, passed in 2019, created a similar state-level dispute resolution process with strict limitations on court review. Under both systems, IDR decisions are intended to be final and binding.
The matter is captioned Blue Cross Blue Shield of Texas v. HaloMD, LLC et al., Case No. 5:25-CV-132-RWS (E.D. Tex.).